The purpose of this study is to learn if the study medication may improve social functioning in 18-30 year old adults with autism spectrum disorder and high brain glutamate compared to placebo. Participants who qualify would be randomly assigned to receive either EM-113 or placebo.
We apply a 21st century, integrated understanding of brain science to create and test novel and better therapies that are urgently needed. We seek new solutions to difficult problems with compassion, creativity and optimism
EM-113 is a novel form of memantine, an FDA-approved NMDA antagonist drug which is already known to be generally safe and well-tolerated in adults with Alzheimer’s disease. It is taken as a capsule once daily.
So far, there are no approved medications to improve the core problems of people with autism, although an imbalance in regulation of brain glutamate may be related to social impairment. An NMDA antagonist may restore glutamate equilibrium without causing new and serious side effects.
Official study title: “A clinical trial of EM-113, an NMDA antagonist, to improve social functioning in participants with autism spectrum disorder and high brain glutamate”
If you are interested in learning more about the study and finding a study site near you, please look for a site below in your area to contact. New sites are opening all the time, so if you don’t find one please check back periodically.
The neurotransmitter glutamate accounts for more than 80% of the brain’s activity. Restoring glutamate balance might be the key to reducing symptoms and improving health and well-being for many people with serious neuropsychiatric conditions including autism spectrum disorder.
EuMentis is developing noncompetitive, low-trapping glutamate antagonists designed to inhibit receptors on neurons that are overly active. EuMentis is combining this clinically-validated approach with novel imaging technology to identify patients with autism spectrum disorder who are most likely to benefit.
